RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: TB4 Provides Both Neuroprotection and Neurorestoration When Administered Shortly after Traumatic Brain Injury in Rat Model  
5/25/2012 10:06:25 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) reported that data showing that Thymosin beta 4 (Tß4) “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI),” was published in the current (May 2012) edition of the Journal of Neurosurgery, 116:1081–1092.